Rituximab treatment of rheumatoid arthritis: new evidence


Cite item

Full Text

Abstract

New evidence is reviewed on efficacy and safety of chimeric monoclonal antibodies to B-cell CD20 molecule (rituximab) in the treatment of rheumatoid arthritis.

About the authors

E L Nasonov

E L Nasonov

References

  1. Насонов Е. Л., Каратеев Д. Е., Балабанова P. M. (ред.) Ревматоидный артрит. В кн.: Насонов Е. Л., Насонова В. А. Ревматология: Нац. руководство. М.: Изд. группа "ГЭОТАР-Медиа"; 2008: 290-331.
  2. Насонова Е. Л. (ред.) Лечение ревматоидного артрита: Клинические рекомендации. М.: изд-во "Алмаз"; 2006.
  3. Bakker M. F., Jacobs J. W. G., Verstappen S. M. M., Bijsma J. W. J. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann. Rheum. Dis. 2007; 66: 56-60.
  4. Saag K. G., Teng G. G., Patkar N. M. et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthr. and Rheum. 2008; 59: 762-784.
  5. Насонов Е. Л. Фармакотерапия ревматоидного артрита - взгляд в 21 век. Клин. мед. 2005; 6: 8-12.
  6. Насонов Е. Л. Фармакотерапия ревматоидного артрита в эру генно-инженерных биологических препаратов. Тер. арх. 2007; 5: 5-8.
  7. Smolen J. S., Aletaha D., Koeller M. et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370: 1861-1871.
  8. Choy E. H., Panayi C. S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 2001; 344: 907-916.
  9. Насонов Е. Л. Применение инфликсимаба (моноклональные антитела к фактору некроза опухоли) в ревматологии: новые данные. Рус. мед. журн. 2004; 20: 1123-1127.
  10. Tracey D., Klareskog L., Sasso E. H. et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 2008; 117: 244-279.
  11. Smolen J. S., Weinblatt M. When patients with rheumatoid arthritis fail tumor necrosis factor inhibitorsL what is the next step? Ann Rheum. Dis. 2008; 67: 1497-1498.
  12. Deng T., Deighton C. Complications of anti-TNF therapies. Future Rheumatol. 2007; 2. on line.
  13. Martin F., Chan A. C. В cell immunobiology in disease: evolving concepts from the clinics. Ann. Rev. Immunol. 2006; 24: 467-496.
  14. Youinou P., Jamin C., Saraux A. B-cell: a logical target for treatment of rheumatoid arthritis. Clin. Exp. Rheumatol. 2007; 25: 318-328.
  15. Sanmarti R., Hernandez M. V., Gomez-Pueta J. A. et al. Serum autoantibodics in rheumatoid arthritis. Int. J. Adv. Rheumatol. 2008; 6: 47-52.
  16. Kuhn K. A., Kulik L., Tomooka B. et al. Antibodies against citrullinated proteins anhance tissue injury in experimental autoimmune arthritis. J. Clin. Invest. 2006; 116: 961-979.
  17. Hansen A., Lipsky P. E., Dorner Т. В cell lymphoproliferation in chronic inflammatory rheumatic diseases. Nat. Clin. Pract. Rheumatol. 2007; 3: 561-570.
  18. Reff M. E., Carner K., Chambers K. S. et al. Depletion of В cells in vivo by a chimeric mouse human antibody to CD20. Blood 1994; 83: 435-445.
  19. Насонов Е. Л. Перспективы применения моноклональных антител к В-лимфоцитам (ритуксимаб) при ревматоидном артрите. Клин. фармакол. и тер. 2006; 1: 55-58.
  20. Насонов Е. Л. Применение ритуксимаба при ревматоидном артрите с позиций медицины, основанной на доказательствах. Тер. арх. 2007; 12: 76-82.
  21. Smolen J. S., Betteridge N., Breedveld F. C. et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2006.
  22. Rituximab for the treatment of rheumatoid arthritis. Nice technology appraisal guidance, 126, 2007.
  23. Furst D. E., Keystone E. C., Kirkham В. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann. Rheum. Dis. 2008; 67: iii2-iii25.
  24. Edwards C. W., Szczepanski L., Szechinski J. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 2005; 350: 2572-2581.
  25. Emery P., Fleishmann R., Filipowicz-Sosnowska A. et al. for the DANCER Study group. The Efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase IIb randomized, double-blind, placebo-controlled dose-range trial. Arthr. and Rneum. 2006; 54: 1390-1400.
  26. Cohen S. B., Emery P., Greenwald M. W. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicentcr, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthr. and Rheum. 2006; 54: 2793-2806.
  27. Emery Р., Rigby W. F., Combe B. et al. Efficacy and Safety of Rituximab (RTX) as first-line biologic therapy in patients with active rheumatoid arthritis: results of a phase III randomized controlled study (SERENA). and ACR 2008, San Francisco, abstr. 364.
  28. Rubbert-Roth A., Tak P. P., Bombardieri S. et al. Efficacy and Safety of various dosing regimens of rituximab in patients with active RA: results of a lace III randomized study (MIRROR). ACR 2008, San Francisco, abstr. 363.
  29. Edwards J. C. W., Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete В lymphocytes. Rheumatology (Oxford) 2001; 40: 205-211.
  30. Leandro M. J., Edwards J. C. W., Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with В lymphocyte depletion. Ann. Rheum. Dis. 2002; 61: 883-888.
  31. De Vita S., Zaja F., Sacco S. et al. Efficacy of selective В cell blockade in the treatment of rheumatoid arthritis. Arthr. and Rheum. 2002; 46: 2029-2033.
  32. Kramm H., Hansen K. E., Gowing E., Bridges A. Successful therapy of rheumatoid arthritis with rituximab. Renewed interest in the role of B cells in the pathogenesis of rheumatoid arthritis. J. Clin. Rheumatol. 2004; 10: 28-32.
  33. Kneitz C., Wilhelm M., Tony H. P. Improvement of refractory rheumatoid arthritis after depletion of B cells. Scand. J. Rheumatol. 2004; 33: 82-86.
  34. Moore J., Ma D., Will R. et al. A phase II study of rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation. Bone Marrow Transplantant. 2004; 34: 241-247.
  35. Gottenberg J.-E., Guillevin L., Lambotte O. et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune disease. Ann. Rheum. Dis. 2005; 64: 913-920.
  36. Higashida J., Wun T., Schmidt S. et al. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-a treatment. J. Rheumatol. 2005; 32: 2109-2115.
  37. Scheinberg M., Hamerschlak N., Kutner J. M. et al. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004). Clin. Exp. Rheumatol. 2006; 24: 65-69.
  38. Brulhart L., Ciurea A., Finckh A. et al. Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor a agent: an open-label observational study. Ann. Rheum. Dis. 2006; 65: 1255-1257.
  39. Jois R. N., Masding A., Somerville M. et al. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience. Rheumatology 2007on.line.
  40. Popa C., Leandro M. J., Cambridge G., Edwards J. C. W. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yers. Rheumatology 2006; December 19.
  41. Bokareva M., Lindholm C., Zendjanchi K. et al. Efficacy of Anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand. J. Immunol. 2007; 66: 467-483.
  42. Assous N., Gossec L., Dieude P. et al. Rituximab therapy in rheumatoid arthritis in daily practice. J. Rheumatol. 2008; 35: 31-34.
  43. McGonagle D., Tan A. L., Madden J. et al. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistent rheumatoid arthritis. Rheumatology 2008; 47: 865-867.
  44. Owczarczyk K., Hellmann M., Fliedner G. et al. Clinival outcome and B cell depletion in patients with rheumatoid arthritis receiving Rituximab monotherapy in comparison with patients receiving concominant methotrexate. Ann. Rheum. Dis. 67: 1648-1650.
  45. Thirling R. M., Vos K., Gerlag D. M., Tak P. Disease activity-guided Rituximab therapy in rheumatoid arthritis. The effects of re-treatment in initial nonresponders versus initial responders. Arthr. and Rheum. 2008; 58: 3657-3664.
  46. van Vollenhoven R. F., Carli C. C., Augustsson J., Klareskog L. Experience with Rituximab in the treatment of rheumatoid arthritis: results from the STURH register. Ann. Rheum. Dis. 2008; 67 (suppl. II): FRI0168.
  47. Vital E. M., Dass S., Rawstron A. C., Emery P. Combination Rituximab and leflunomide produces lasting responses in rheumatoid arthritis. Ann. Rheum Dis. 2008; 67 (suppl. II): 90 (OP-0134).
  48. Dass S., Vital E. M., Buch M. H. et al. Rituximab treatment for RA: experience of the first 100 patients treated at a single center. Ann. Rheum. Dis. 2008; 67 (suppl. II): (АВ0352).
  49. Guzman R. A., Mera M. V., Roa G. М. et al. Rituximab: early use in patients with rheumatoid arthritis refractory to DMARD. Ann. Rheum. Dis. 2008; 67 (suppl. II): 358.
  50. Haraoui B., Bokareva M., Kallmeyer I., Bykerk V. ACR and DAS 28 response over 24 weeks in RA patients treated with rituximab after an inadequate response to one TNF inhibitor. Ann. Rheum. Dis. 2008; 67 (suppl. II): (ABO360).
  51. Gottenberg J.-E., Ravaud P., Bardin T. et al. Prospective follow-up rituximab treatment in 965 patients with refractory rheumatoid arthritis (630 patients/year); tolerance and efficacy data from French Register AIR (Autoimmunity and Rituximab) / ACR 2008; San Francisco; 1190 (abst).
  52. Strangfeld A., Hierse F., Listing J. et al. RA patients treated with Rituximab - routine care data of the German Biologics Register RABBIT. ACR 2008, San Francisco; 371 (abst).
  53. Hazlewood G., Barnabe C., Bass S., Martin L. Use of Rituximab in severe rheumatoid arthritis: "real-world" experience in a Canadian Center. ACR. 2008, San Francisco, F96 (abst).
  54. De la Torre I., Gonzalez C. M., Cebrian L. et al. Rituximab additional treatment courses in patients with rheumatoid arthritis in daily practice. Ann. Rheum. Dis. 2008; 67 (suppl. II): AВ0356.
  55. Dohn U. M., Bird P., Ostergaard M. et al. Rheumatoid arthritis (RA) patients treated with Rituximab showed no mean erosive progression, but a small tendency toward regression, on magnetic resonance imagine (MRI) and conventional radiography 1 year after treatment. Ann. Rheum. Dis. 2008; 67 (suppl. II): 107 (OP-0185).
  56. Насонов Е. Л., Лукина Г. В., Сигидин Я. А. и др. Применение моноклональных антител к В-лимфоцитам (ритуксимаб) при ревматоидном артрите в России (Предварительные результаты Российского регистра). Тер. арх. 2008; 8: 57-63.
  57. Keystone E., Fleishmann R., Emery P. et al. Safety and efficacy of additional course of rituximab in patients with active rheumatoid arthritis. An open-label extension analysis. Arthr. and Pheum. 2007; 56: 3896-3908.
  58. Keystone E. C., Emery P., Peterfy C. G. et al. Rituximab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapies. Ann. Rheum. Dis. 2008, 3 April on line.
  59. Keystone E. C., Fleishmann R. M., Emery P. et al. Efficacy and safety of repeat treatment courses of Rituximab in RA patients with inadequate response to tumor necrosis factor inhibitors: long-term experience from REFLEX study. ACR 2008; San Francisco, 367 (abst).
  60. Cohen S., Keystone E., Genovese M. et al. Continued inhibition of structural damage in rheumatoid arthritis patients treated with Rituximab at 2 years: REFLEX study. ACR 2008; San Francisco; 368 (abst).
  61. Mease P. J., Cohen S., Gaylis N. B. et al. Efficacy, Safety, and dose frequency of retreatment with Rituximab in RA: results from a randomizen controlled trial (SUNRISE). ACR 2008, San Francisco; 1212 (abst).
  62. Teng Y., Tekstra J., Breedveld F. C. et al. Rituximab fixed re-treatment versus on-demand re-treatment in refractory rheumatoid arthritis. Ann. Rheum. Dis. 2008; 67 (suppl. II): 339 (FRI0167).
  63. Owczarczyk K., Maizus K., Roehrs T. et al. The clinical efficacy of repeated courses of rituximab and the kinetics of B cell depletion in primary Rituximab non-responders. ACR 2008; San Francisco; 1002.
  64. Lutt J. R., Deodhar A. Rheumatoid arthritis. Strategies in the management of patients showing an adequate response to TNFa antagonist. Drugs 2008; 66: 591-606.
  65. Finckh A., Ciurea A., Brulhart L. et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthr. and Rheum. 2007; 56: 1417-1423.
  66. Finckh A., Ciurea A., Brulhart L. et al. Which subgroup of rheumatoid arthritis patients benefit most from switching to rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agents? Ann. Rheum. Dis. 2008; 67 (suppl. II): 127 (OP-0249).
  67. van Vollenhoven R. F., Carli C. C. The efficacy of rituximab in patients with rheumatoid arthritis (RA) who previously failed one or two ant-TNFs as compared to the efficacy of switching between ant-TNFs; a registry study. ACR 2008, San Francisco; 1995 (abst).
  68. Blom M., Kievit W., den Broeder A. et al. Comparison of the Effectiveness of Rituximab and a third TNF blocking agents after failure of two TNF blocking agents in daily clinical practice. ACR 2008; San Francisco; 370 (abst).
  69. Smolen J., Kay J., Doyle M. K. et al. Golimumab, a new human antiOTNF monoclonal antibody, suscutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-alpha agents; results of the randomized, double-blind, placebo-c. Ann. Rheum. Dis. 2008; 67 (suppl. II): OP0010.
  70. Alvarez C., Brown B., Aristides M. et al. Cost analysis of introducing rituximab as new treatment approach for rheumatoid arthritis: the Spanish perspective. Ann. Rheum. Dis. 2006; 65 (suppl. II): 273 (THU0521).
  71. Payet S., Francesconi C., Rioufranca L. et al. Budget impact of rituximab (MABRHERA) after failure of one or more TNF inhibitor therapies in the treatment of rheumatoid arthritis. Ann. Rheum. Dis. 2007; 66 (suppl. II): 435 (SAT0024).
  72. Fleischmann R. M. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases; focus on Rituximab. Semin. Arthr. Rheum. 2008, on line.
  73. Pham T., Fautrel B., Gottenberg J.-E. et al. Rituximab (MabThera) therapy and safethy management. Joint Bone Spain 2008; 75: (suppl. 1): S1-S100.
  74. Salliot C., Dougados M., Gossec L. Risk of serious infections during rituximab, abatacept and anakinra for rheumatoid arthritis: meta analysis of randomized placebo-controlled trials. Ann. Rheum. Dis. 2008, Jan 18, on line.
  75. van Vollenhoven R. F., Emery P., Bingham C. O. et al. Long-term safety of rituximab: 6-year follow-up of the RA clinical trials and re-treatment-population. ACR 2008; San Francisco; 361 (abst).
  76. Genovese M., Breedveld F., Emery P. et al. Safety of other biologic therapies following rituximab treatment in RA patients. ACR 2008, San Francisco, 1671 (abst).
  77. Blank N., Max R., Briem S. et al. Combination therapy with Rituximab and etanercept for patients with rheumatoid arthritis. Ann. Rheum. Dis. 2008; 67 (suppl. II): 188.
  78. van Vollenhoven R. F., Gabay C., Hetland M. L. et al. Seven-hundred and fifty patients treated with rituximab for RA in European Registers: base-lane data analysis from collaboration European Registeries for Rituximab in RA (CERERRA). ACR 2008, San Francisco; 362 (abst).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies